alexa

GET THE APP

Investigating The Nexus Between DNA Repair Pathways And Genomic Instability In Cancer | 97815
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1536

Journal of Biotechnology & Biomaterials received 1536 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Investigating the nexus between DNA repair pathways and genomic instability in cancer

Joint Event on 24th Biotechnology Congress: Research & Innovations & Annual Congress on CRISPR Cas9 Technology and Genetic Engineering

Sonali Bhattacharjee

Cold Spring Harbor Laboratory, USA

Keynote: J Biotechnol Biomater

DOI: 10.4172/2155-952X-C4-096

Abstract
DNA double-strand breaks are one of the most lethal lesions to a cell that can be repaired by one of the two cellular pathways; non-homologous end joining or homologous recombination. Homologous recombination genes are particularly attractive targets for precision cancer therapy because these genes have altered expression patterns in cancer cells when compared with normal cells and these genetic abnormalities can be targeted for selectively killing cancer cells while leaving normal cells unscathed. Synthetic lethality is thought to be the new frontier of cancer therapeutics because it overcomes the limitation of chemotherapy, which is unable to discriminate between cancer cells and normal cells. Two genes are synthetically lethal when simultaneous disruptions of both genes give rise to a lethal phenotype, while the disruption of either gene alone is viable. Many homologous recombination genes have synthetic lethal relationships with oncogenes and tumor suppressor genes, which can be targeted for the development of cancer therapy- an approach referred to as combination therapy. In my presentation, I will summarize recent progress in understanding both the functioning and the regulation of the DNA repair machinery and elaborate on the clinical applications of these proteins in cancer therapy.
Biography

Sonali Bhattacharjee did her BSc in Biotechnology from Bangalore University in 2006 and MSc in Applied Genetics from Bangalore University in 2008. She then moved to England to pursue her DPhil (Phd) in Biochemistry from Oxford University where she studied the role of Fml1 and its partner proteins MHF1 and MHF2 in promoting genome stability. She was awarded her DPhil in 2012. During her time at Oxford, she was also a tutor at Greene’s College, Oxford. In 2013, she moved to Cold Spring Harbor Laboratory, New York. At CSHL, her work has focused on understanding the epigenetic regulation of DNA repair. She is also an academic tutor at the Watson School of Biological studies, the school for graduate studies at CSHL

E-mail: [email protected]

 

Top